Quantification of increased biologically active CXCL12α plasma concentrations after ACKR3 antagonist treatment in humans

Documenti analoghi

• The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239
  di: Christine Huynh, et al.
  Pubblicazione: (2024)
• Elevated plasma CXCL9 and CHI3L1 prior to HCT predict post‐HCT lung complications in children
  di: Hannah Walker, et al.
  Pubblicazione: (2025)
• The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant
  di: Ingrid Koopmans, et al.
  Pubblicazione: (2024)
• RETRACTION : Mechanism of ARPP21 antagonistic intron miR ‐128 on neurological function repair after stroke
  Pubblicazione: (2024)
• α‐Synuclein species in plasma neuron‐derived extracellular vesicles as biomarkers for iRBD
  di: Xuemei Wang, et al.
  Pubblicazione: (2024)